Partial treatment response to capmatinib in MET -amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature

Cholangiocarcinoma is a highly morbid gastrointestinal malignancy for which available therapies are limited. Standard of care includes cytotoxic chemotherapies such as gemcitabine, platinum agents, nab-paclitaxel, and fluoropyrimidine analogues. However, tolerability of these regimens varies, and pa...

Full description

Saved in:
Bibliographic Details
Published in:Cancer biology & therapy 2022-12, Vol.23 (1), p.112-116
Main Authors: Lefler, Daniel S, Tierno, Marni Brisson, Bashir, Babar
Format: Article
Language:English
Subjects:
Bedside-to-Bench Report
Benzamides
Bile Duct Neoplasms - drug therapy
Bile Duct Neoplasms - genetics
Bile Duct Neoplasms - pathology
Bile Ducts, Intrahepatic - pathology
capmatinib
Carcinoma, Non-Small-Cell Lung - pathology
cholangiocarcinoma
Cholangiocarcinoma - drug therapy
Cholangiocarcinoma - genetics
Humans
Imidazoles
Lung Neoplasms - pathology
met amplification
met gene
Proto-Oncogene Proteins c-met - genetics
targeted therapy
Triazines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cholangiocarcinoma is a highly morbid gastrointestinal malignancy for which available therapies are limited. Standard of care includes cytotoxic chemotherapies such as gemcitabine, platinum agents, nab-paclitaxel, and fluoropyrimidine analogues. However, tolerability of these regimens varies, and patients who do not tolerate chemotherapy have limited targeted therapies and immunotherapy options. In cholangiocarcinoma, mesenchymal-epithelial transition factor ( amplification may present an additional opportunity for a targeted therapeutic approach, especially considering emerging data in non-small cell lung cancer. In this case, we present a metastatic cholangiocarcinoma patient with high-level gene amplification for whom capmatinib, a tyrosine kinase inhibitor with activity against c-MET, provided a partial response after cessation of chemotherapy.
ISSN:1538-4047
1555-8576
DOI:10.1080/15384047.2022.2029128